Total Articles:
886,158 Total Authors:
151,791 Total Downloads:
19,356,238
Newest Member Malka Ladick
Text Ad's
Fluoroquinolone Antibiotics Classification, Uses and Unwanted effects The fluoroquinolones really are a relatively new number of antibiotics. Fluoroquinolones were first introduced in 1986, but they can also be really modified quinolones, a program of ant
The fluoroquinolones absolutely are a breed of synthetic, broad-spectrum antibacterial agents with bactericidal activity. The parent of a typical group is nalidixic acid, discovered in 1962 by Lescher and colleagues. The initial fluoroquinolones were widely used because they were the only orally administered agents intended for treating serious infections because of gram-negative organisms, including Pseudomonas species.
The newer fluoroquinolones have a wider clinical use and a broader spectrum of antibacterial activity including gram-positive and gram-negative aerobic and anaerobic organisms. A few of the newer fluoroquinolones contain an important function in managing community-acquired pneumonia and intra-abdominal infections.
Fluoroquinolones disadvantages:
Tendonitis or tendon rupture
Multiple drug interactions
Not used in children
Newer quinolones produce additional toxicities to your heart that were not found together with the older brokers
Fluoroquinolones advantages:
Ease of administration
Daily or twice daily dosing
Excellent oral absorption
Excellent tissue penetration
Prolonged half-lives
Significant entry into phagocytic cells
Efficacy
Overall safety
Classification of Fluoroquinolones
To be a group, the fluoroquinolones have excellent in vitro activity against a large choice of both gram-positive and gram-negative bacteria. Modern-day fluoroquinolones have enhanced activity against gram-positive bacteria with just the lowest lowering of activity against gram-negative bacteria. Their expanded gram-positive activity is very important as it includes significant activity against Streptococcus pneumoniae.
First Generation. The first-generation agents include cinoxacin and nalidixic acid, which are the oldest and least often used quinolones. These drugs had poor systemic distribution and limited activity and were utilized primarily for gram-negative urinary tract infections. Cinoxacin and nalidixic acid require more frequent dosing compared to the newer quinolones, and are also more susceptible towards the development of bacterial resistance.
Second Generation. The second-generation fluoroquinolones have increased gram-negative activity, and also some gram-positive and atypical pathogen coverage. When compared with first-generation quinolones, these drugs have broader clinical applications in the remedy for complicated urinary tract infections and pyelonephritis, sexually transmitted diseases, selected pneumonias and skin infections.
Second-generation agents include ciprofloxacin, enoxacin, lomefloxacin, norfloxacin and ofloxacin. Ciprofloxacin is the most potent fluoroquinolone against P. aeruginosa. Ciprofloxacin and ofloxacin would be the hottest second-generation quinolones because of their availability in oral and intravenous formulations as well as their broad range of FDA-labeled indications.
Third Generation. The third-generation fluoroquinolones are separated into a third class because of their expanded activity against gram-positive organisms, particularly penicillin-sensitive and penicillin-resistant S. pneumoniae, and atypical pathogens similar to Mycoplasma pneumoniae and Chlamydia pneumoniae. Even though third-generation agents retain broad gram-negative coverage, these are less active than ciprofloxacin against Pseudomonas species.
Because of the expanded antimicrobial spectrum, third-generation fluoroquinolones are of help within the treatment of community-acquired pneumonia, acute sinusitis and acute exacerbations of chronic bronchitis, that their primary FDA-labeled indications. The third-generation fluoroquinolones include levofloxacin, gatifloxacin, moxifloxacin and sparfloxacin.
Fourth Generation. The fourth-generation fluoroquinolones add significant antimicrobial activity against anaerobes while keeping the gram-positive and gram-negative workings of the third-generation drugs. In addition they retain activity against Pseudomonas species akin to that of ciprofloxacin. The fourth-generation fluoroquinolones include trovafloxacin (Trovan).
Because of be worried about hepatotoxicity, trovafloxacin therapy should really be available to life- or limb-threatening infections requiring inpatient treatment (hospital or long-term care facility), and the drug should be taken for not than 14 days.
Unwanted side effects
The fluoroquinolones being a class are generally well tolerated. Most adverse effects are mild in severity, self-limited, and infrequently induce treatment discontinuation. However, they often have serious negative effects.
Fluoroquinolones are approved for use only in people older than 18. They can affect the development of bones, teeth, and cartilage inside of a child or fetus. The FDA has assigned fluoroquinolones to pregnancy risk category C, indicating when these drugs have the potential to cause teratogenic or embryocidal effects. Giving fluoroquinolones while pregnant will never be recommended unless the advantages justify the possible risks to your fetus. These agents can be excreted in breast milk and may even be avoided during breast-feeding if at all possible.
Gastrointestinal effects. The most common adverse events informed about fluoroquinolone administration are gastrointestinal (nausea, vomiting, diarrhea, constipation, and abdominal pain), which occur in a single to 5% of patients.
CNS effects. Headache, dizziness, and drowsiness are actually reported with fluoroquinolones. Insomnia was reported in 3-7% of patients with ofloxacin. Severe CNS effects, including seizures, are actually reported in patients receiving trovafloxacin. Seizures may develop within three to four days of therapy but resolve with drug discontinuation. Although seizures are infrequent, fluoroquinolones should be avoided in patients with a history of convulsion, cerebral trauma, or anoxia. No seizures seem to have been reported with levofloxacin, moxifloxacin, gatifloxacin, and gemifloxacin. With all the older non-fluorinated quinolones neurotoxic symptoms similar to dizziness happened about 50% of the patients.
Phototoxicity. Exposure to ultraviolet A rays from direct or indirect sunlight ought to be avoided during treatment and several days (5 days with sparfloxacin) after the utilization of the medication. The degree of phototoxic potential of fluoroquinolones is often as follows: lomefloxacin > sparfloxacin > ciprofloxacin > norfloxacin = ofloxacin = levofloxacin = gatifloxacin = moxifloxacin.
Musculoskeletal effects. Concern about the introduction of musculoskeletal effects, evident in animal studies, has led to your contraindication of fluoroquinolones for routine use in children and in women who are pregnant or lactating.
Tendon damage (tendinitis and tendon rupture). Although fluoroquinolone-related tendinitis generally resolves within 7 days of discontinuation of therapy, spontaneous ruptures seem to have been reported as long as nine months after cessation of fluoroquinolone use. Potential risk factors for tendinopathy include age >50 years, male gender, and concomitant consumption of corticosteroids.
Hepatoxicity. Trovafloxacin use has been involved with rare liver damage, which prompted the withdrawal of many oral preparations coming from the U.S. market. However, the IV preparation is available for treatment of infections so serious the benefits outweigh the risks.
Cardiovascular effects. The newer quinolones have been found to provide additional toxicities to the heart which were not found in the older compounds. Evidence means that sparfloxacin and grepafloxacin can have the most cardiotoxic potential.
Hypoglycemia/Hyperglycemia. Recently, rare cases of hypoglycemia have already been reported with gatifloxacin and ciprofloxacin in patients also receiving oral diabetic medications, primarily sulfonylureas. Although hypoglycemia is reported with other fluoroquinolones (levofloxacin and moxifloxacin), the results seem to have been mild.
Hypersensitivity. Hypersensitivity reactions occur only occasionally during quinolone therapy and are generally mild to moderate in severity, and frequently resolve after treatment is stopped.
Conditions treated with Fluoroquinolones: indications and uses
The newer fluoroquinolones have a very wider clinical use as well as a broader spectrum of antibacterial activity including gram-positive and gram-negative aerobic and anaerobic organisms. A few of the newer fluoroquinolones posses important aspect in handling community-acquired pneumonia and intra-abdominal infections. The serum elimination half-life of your fluoroquinolones range from 3 -20 hours, allowing for once or twice daily dosing.
Author Resource:-
The fluoroquinolones absolutely are a breed of synthetic, broad-spectrum antibacterial agents with bactericidal activity. The parent of the group is nalidixic acid, found in 1962 by Lescher and colleagues. The initial fluoroquinolones were widely used because they were the sole orally administered agents available for treating serious infections caused by gram-negative organisms, including Pseudomonas species.
The newer fluoroquinolones have a very wider clinical use and a broader spectrum of antibacterial activity including gram-positive and gram-negative aerobic and anaerobic organisms. A number of the newer fluoroquinolones posses important function in the treatment of community-acquired pneumonia and intra-abdominal infections.
Fluoroquinolones disadvantages:
Tendonitis or tendon rupture
Multiple drug interactions
Not used in kids
Newer quinolones produce additional toxicities into the heart that were not found together with the older elements
Fluoroquinolones advantages:
Simplicity of administration
Daily or twice daily dosing
Excellent oral absorption
Excellent tissue penetration
Prolonged half-lives
Significant entry into phagocytic cells
Efficacy
Overall safety
Classification of Fluoroquinolones
Being a group, the fluoroquinolones have excellent in vitro activity against a wide range of both gram-positive and gram-negative bacteria. The newest fluoroquinolones have enhanced activity against gram-positive bacteria with just the a decreased discount in activity against gram-negative bacteria. Their expanded gram-positive activity is extremely important this is because includes significant activity against Streptococcus pneumoniae.
First Generation. The first-generation agents include cinoxacin and nalidixic acid, knowing the oldest and least often used quinolones. These drugs had poor systemic distribution and limited activity and were chosen primarily for gram-negative urinary tract infections. Cinoxacin and nalidixic acid require more frequent dosing compared to the newer quinolones, plus they are also more susceptible into the development of bacterial resistance.
Second Generation. The second-generation fluoroquinolones have increased gram-negative activity, as well as some gram-positive and atypical pathogen coverage. Compared with first-generation quinolones, these drugs have broader clinical applications within the treatment of complicated urinary tract infections and pyelonephritis, stds, selected pneumonias and skin infections.
Second-generation agents include ciprofloxacin, enoxacin, lomefloxacin, norfloxacin and ofloxacin. Ciprofloxacin will be the most potent fluoroquinolone against P. aeruginosa. Ciprofloxacin and ofloxacin are classified as the preferred second-generation quinolones due to availability in oral and intravenous formulations and their broad group of FDA-labeled indications.
Third Generation. The third-generation fluoroquinolones are separated right into a third class due to expanded activity against gram-positive organisms, particularly penicillin-sensitive and penicillin-resistant S. pneumoniae, and atypical pathogens for instance Mycoplasma pneumoniae and Chlamydia pneumoniae. Even though third-generation agents retain broad gram-negative coverage, they're less active than ciprofloxacin against Pseudomonas species.
Because of their expanded antimicrobial spectrum, third-generation fluoroquinolones are helpful throughout remedy for community-acquired pneumonia, acute sinusitis and acute exacerbations of chronic bronchitis, that happen to be their primary FDA-labeled indications. The third-generation fluoroquinolones include levofloxacin, gatifloxacin, moxifloxacin and sparfloxacin.
Fourth Generation. The fourth-generation fluoroquinolones add significant antimicrobial activity against anaerobes while maintaining the gram-positive and gram-negative activity of the third-generation drugs. They also retain activity against Pseudomonas species akin to that of ciprofloxacin. The fourth-generation fluoroquinolones include trovafloxacin (Trovan).
Owing to be worried about hepatotoxicity, trovafloxacin therapy really should be ready for life- or limb-threatening infections requiring inpatient treatment (hospital or long-term care facility), as well as the drug should be taken for not than 14 days.
Unwanted side effects
The fluoroquinolones being a class are generally well tolerated. Most negative effects are mild in severity, self-limited, and barely induce treatment discontinuation. However, they could have serious uncomfortable side effects.
Fluoroquinolones are approved for use only in people older than 18. They could affect the growth of bones, teeth, and cartilage inside a child or fetus. The FDA has assigned fluoroquinolones to pregnancy risk category C, indicating when these drugs have the possibility to cause teratogenic or embryocidal effects. Giving fluoroquinolones when you are pregnant will not be recommended unless the advantages justify the new risks towards the fetus. These agents can also be excreted in breast milk and may be ignored during breast-feeding if at all possible.
Gastrointestinal effects. The biggest commonplace adverse events familiar with fluoroquinolone administration are gastrointestinal (nausea, vomiting, diarrhea, constipation, and abdominal pain), which occur approx 1 to 5% of patients.
CNS effects. Headache, dizziness, and drowsiness have been reported with fluoroquinolones. Insomnia was reported in 3-7% of patients with ofloxacin. Severe CNS effects, including seizures, have already been reported in patients receiving trovafloxacin. Seizures may develop within three or four times of therapy but resolve with drug discontinuation. Although seizures are infrequent, fluoroquinolones really should be avoided in patients which has a roots or history of convulsion, cerebral trauma, or anoxia. No seizures are actually reported with levofloxacin, moxifloxacin, gatifloxacin, and gemifloxacin. In the older non-fluorinated quinolones neurotoxic symptoms such as dizziness took place in about 50% of the patients.
Phototoxicity. Exposure to ultraviolet A rays from direct or indirect sunlight should be avoided during treatment and a number of other days (5 days with sparfloxacin) following the consumption of the drug. The degree of phototoxic potential of fluoroquinolones is as follows: lomefloxacin > sparfloxacin > ciprofloxacin > norfloxacin = ofloxacin = levofloxacin = gatifloxacin = moxifloxacin.
Musculoskeletal effects. Worry about the creation of musculoskeletal effects, evident in animal studies, has led into the contraindication of fluoroquinolones for routine use in children whereas in the women who are pregnant or lactating.
Tendon damage (tendinitis and tendon rupture). Although fluoroquinolone-related tendinitis generally resolves within 7 days of discontinuation of therapy, spontaneous ruptures seem to have been reported as long as nine months after cessation of fluoroquinolone use. Potential risk factors for tendinopathy include age >50 years, male gender, and concomitant utilization of corticosteroids.
Hepatoxicity. Trovafloxacin use is associated with rare liver damage, which prompted the withdrawal of a typical oral preparations that came from the U.S. market. However, the IV preparation is readily available for remedy for infections so serious which the benefits outweigh the risks.
Cardiovascular effects. The newer quinolones have already been found to provide additional toxicities to the heart which were not found together with the older compounds. Evidence advices sparfloxacin and grepafloxacin could possibly have essentially the most cardiotoxic potential.
Hypoglycemia/Hyperglycemia. Recently, rare cases of hypoglycemia seem to have been reported with gatifloxacin and ciprofloxacin in patients also receiving oral diabetic medications, primarily sulfonylureas. Although hypoglycemia has been reported with other fluoroquinolones (levofloxacin and moxifloxacin), the consequences have already been mild.
Hypersensitivity. Hypersensitivity reactions occur only occasionally during quinolone therapy and can be mild to moderate in severity, and frequently resolve after treatment is stopped.
Conditions treated with Fluoroquinolones: indications and uses
The newer fluoroquinolones have a wider clinical use plus a broader spectrum of antibacterial activity including gram-positive and gram-negative aerobic and anaerobic organisms. Many of the newer fluoroquinolones have an important role in handling community-acquired pneumonia and intra-abdominal infections. The serum elimination half-life of many fluoroquinolones be 3 -20 hours, letting maybe once or twice daily dosing.
![[Valid RSS feed]](http://article2008.com/images/feed-icon.png "XML Feed For RSS"){kind=icon}
![[Valid RSS feed]](http://article2008.com/images/icon_Rss.png "XML Feed For RSS"){kind=icon}
Category Rss Feed
Print This Article
Add To Favorites